$NKTR
Nektar Therapeutics

2015 Q2 Form 10-Q Financial Statement

#000119312515163717 Filed on May 01, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q4
Revenue $22.66M $108.8M $19.55M
YoY Change -20.52% 450.31% -37.23%
Cost Of Revenue $10.53M $8.444M $6.298M
YoY Change 106.23% 6.79% -29.71%
Gross Profit $12.13M $100.4M $13.25M
YoY Change -48.19% 745.9% -40.26%
Gross Profit Margin 53.51% 92.24% 67.79%
Selling, General & Admin $10.20M $10.30M $12.20M
YoY Change 6.25% 4.04% 24.49%
% of Gross Profit 84.11% 10.26% 92.05%
Research & Development $45.41M $47.01M $38.49M
YoY Change 23.73% 22.62% -20.22%
% of Gross Profit 374.47% 46.84% 290.45%
Depreciation & Amortization $2.800M $3.000M $3.200M
YoY Change -12.5% -9.09% -5.88%
% of Gross Profit 23.09% 2.99% 24.15%
Operating Expenses $45.41M $47.01M $38.49M
YoY Change 23.73% 22.62% -20.22%
Operating Profit -$43.47M $43.04M -$37.49M
YoY Change 89.69% -218.24% 4.44%
Interest Expense $4.118M $4.171M -$9.300M
YoY Change -8.24% -7.99% -7.92%
% of Operating Profit 9.69%
Other Income/Expense, Net -$9.024M -$9.010M
YoY Change -5.27% -6.22%
Pretax Income -$52.49M $34.03M -$46.80M
YoY Change 61.81% -173.97% 1.74%
Income Tax $164.0K $213.0K -$1.100M
% Of Pretax Income 0.63%
Net Earnings -$52.66M $33.82M -$45.68M
YoY Change 61.34% -173.2% -4.15%
Net Earnings / Revenue -232.37% 31.08% -233.66%
Basic Earnings Per Share -$0.40 $0.26 -$0.35
Diluted Earnings Per Share -$0.40 $0.25 -$0.35
COMMON SHARES
Basic Shares Outstanding 131.5M shares 131.4M 128.4M shares
Diluted Shares Outstanding 135.7M

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $254.7M $300.8M $237.8M
YoY Change -7.85% 5.88% 0.34%
Cash & Equivalents $20.88M $129.5M $12.37M
Short-Term Investments $233.8M $171.4M $225.5M
Other Short-Term Assets $8.782M $6.092M $8.817M
YoY Change 89.72% 2.01% 70.38%
Inventory $10.12M $12.51M $12.95M
Prepaid Expenses
Receivables $3.680M $2.885M $3.607M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $302.2M $347.3M $288.2M
YoY Change 1.35% 13.95% 11.76%
LONG-TERM ASSETS
Property, Plant & Equipment $72.16M $69.27M $70.37M
YoY Change 1.53% -5.07% 5.07%
Goodwill $76.50M $76.50M $76.50M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.762M $6.151M $6.552M
YoY Change -21.53% -20.88% -19.8%
Total Long-Term Assets $154.4M $151.9M $153.4M
YoY Change -14.17% -16.64% -13.15%
TOTAL ASSETS
Total Short-Term Assets $302.2M $347.3M $288.2M
Total Long-Term Assets $154.4M $151.9M $153.4M
Total Assets $456.7M $499.2M $441.6M
YoY Change -4.49% 2.5% 1.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.833M $5.024M $2.703M
YoY Change -61.91% 63.97% -70.35%
Accrued Expenses $36.40M $8.245M $6.418M
YoY Change 526.07% 20.88% 2.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.600M $5.400M $4.500M
YoY Change
Total Short-Term Liabilities $81.08M $75.44M $64.05M
YoY Change -3.89% -4.88% -34.79%
LONG-TERM LIABILITIES
Long-Term Debt $127.9M $129.4M $129.1M
YoY Change -36.37% -35.97% -36.4%
Other Long-Term Liabilities $16.67M $17.10M $14.72M
YoY Change -6.19% -3.8% -23.55%
Total Long-Term Liabilities $16.67M $17.10M $14.72M
YoY Change -6.19% -3.8% -23.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $81.08M $75.44M $64.05M
Total Long-Term Liabilities $16.67M $17.10M $14.72M
Total Liabilities $421.6M $421.9M $405.3M
YoY Change -17.9% -15.08% -22.72%
SHAREHOLDERS EQUITY
Retained Earnings -$1.805B -$1.752B -$1.786B
YoY Change -0.34% -1.47% 3.11%
Common Stock $1.842B $1.831B $1.824B
YoY Change 3.66% 3.47% 10.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.10M $77.31M $36.33M
YoY Change
Total Liabilities & Shareholders Equity $456.7M $499.2M $441.6M
YoY Change -4.49% 2.5% 1.63%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q4
OPERATING ACTIVITIES
Net Income -$52.66M $33.82M -$45.68M
YoY Change 61.34% -173.2% -4.15%
Depreciation, Depletion And Amortization $2.800M $3.000M $3.200M
YoY Change -12.5% -9.09% -5.88%
Cash From Operating Activities -$47.20M $63.30M -$24.60M
YoY Change 418.68% -201.61% -145.81%
INVESTING ACTIVITIES
Capital Expenditures -$3.500M $1.059M -$3.900M
YoY Change 400.0% -76.59% 44.44%
Acquisitions
YoY Change
Other Investing Activities -$62.50M $54.20M -$20.90M
YoY Change -1141.67% -200.93% -73.68%
Cash From Investing Activities -$66.00M $53.20M -$24.80M
YoY Change -1345.28% -191.41% -69.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.700M 600.0K 29.90M
YoY Change 135.0% -99.47% 1323.81%
NET CHANGE
Cash From Operating Activities -47.20M 63.30M -24.60M
Cash From Investing Activities -66.00M 53.20M -24.80M
Cash From Financing Activities 4.700M 600.0K 29.90M
Net Change In Cash -108.5M 117.1M -19.50M
YoY Change 5927.78% -1874.24% -26.14%
FREE CASH FLOW
Cash From Operating Activities -$47.20M $63.30M -$24.60M
Capital Expenditures -$3.500M $1.059M -$3.900M
Free Cash Flow -$43.70M $62.24M -$20.70M
YoY Change 420.24% -193.14% -136.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131526201 shares
CY2014Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2014Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32443000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131451000 shares
CY2015Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
171353000
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
6092000
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131451000 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
125000000
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10534000
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
78418000
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
75444000
CY2015Q1 us-gaap Capital Lease Obligations
CapitalLeaseObligations
9800000
CY2015Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
4386000
CY2015Q1 us-gaap Interest Payable Current
InterestPayableCurrent
3167000
CY2015Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
13000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1276000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5024000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1752489000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1831057000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8245000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
77305000
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17101000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
499212000
CY2015Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24959000
CY2015Q1 us-gaap Liabilities
Liabilities
421907000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9356000
CY2015Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
5412000
CY2015Q1 us-gaap Long Term Debt
LongTermDebt
134800000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129452000
CY2015Q1 us-gaap Goodwill
Goodwill
76501000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69267000
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
25000000
CY2015Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
171353000
CY2015Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2445000
CY2015Q1 us-gaap Assets
Assets
499212000
CY2015Q1 us-gaap Inventory Net
InventoryNet
12511000
CY2015Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2401000
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2885000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6151000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
347293000
CY2015Q1 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
121558000
CY2015Q1 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
8747000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39067000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131216000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131216000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7665000
CY2015Q1 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
325805000
CY2015Q1 nktr Cash And Restricted Cash
CashAndRestrictedCash
30894000
CY2015Q1 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
125000000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5567000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
76911000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64047000
CY2014Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
4139000
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
6917000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1567000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2703000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1786309000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1824195000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6418000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
36332000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14721000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
441621000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24473000
CY2014Q4 us-gaap Liabilities
Liabilities
405289000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5749000
CY2014Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
4512000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12365000
CY2014Q4 us-gaap Goodwill
Goodwill
76501000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70368000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
25000000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
225459000
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5565000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38338000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6624000
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
191000
CY2014Q4 us-gaap Assets
Assets
441621000
CY2014Q4 us-gaap Inventory Net
InventoryNet
12952000
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2200000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3607000
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
225459000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8817000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6552000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
288200000
CY2014Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5187000
CY2014Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
262824000
CY2014Q4 nktr Cash And Restricted Cash
CashAndRestrictedCash
26136000
CY2014Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2014Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
120471000
CY2014Q4 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
7708000
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2014Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.34 pure
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-62290000
CY2014Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
667374 shares
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123543000 shares
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
123543000 shares
CY2014Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
110661000
CY2014Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
825000
CY2014Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
718000
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-580000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46010000
CY2014Q1 us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
0.0
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36402000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45960000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9608000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
312000
CY2014Q1 us-gaap Revenues
Revenues
19771000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4524000
CY2014Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-777000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-46201000
CY2014Q1 us-gaap Interest Paid
InterestPaid
7961000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-374000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4361000
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
11000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5957000
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4827000
CY2014Q1 us-gaap Interest Expense
InterestExpense
4533000
CY2014Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7907000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3264000
CY2014Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-3750000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
113868000
CY2014Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
5074000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
693000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-58213000
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
56173000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9928000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6126000
CY2014Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
56972000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4361000
CY2014Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1195000
CY2014Q1 nktr Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs
RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts
-7000000
CY2014Q1 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
8081000
CY2014Q1 nktr Product Sales And Royalties
ProductSalesAndRoyalties
5917000
CY2014Q1 nktr Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
116619000
CY2014Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
5773000
CY2014Q1 nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
-3179000
CY2014Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
5387000
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
CY2015Q1 dei Trading Symbol
TradingSymbol
NKTR
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
34033000
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.34 pure
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
63312000
CY2015Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
235298 shares
CY2015Q1 us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
5200000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
43043000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
34111000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9010000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
211000
CY2015Q1 us-gaap Revenues
Revenues
108801000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1059000
CY2015Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
938000
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, we evaluate our estimates, including those related to estimated selling prices of deliverables in collaboration agreements, estimated periods of performance, the net realizable value of inventory, the impairment of investments, the impairment of goodwill and long-lived assets, contingencies, accrued clinical trial expenses, estimated interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information and any changes in estimates will generally be reflected in the period first identified.</p> </div>
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135667000 shares
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-441000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000906709
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Reclassifications</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating income (loss), net income (loss), total assets, liabilities or stockholders&#x2019; equity.</p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131359000 shares
CY2015Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
24432000
CY2015Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1098000
CY2015Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2809000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
33820000
CY2015Q1 us-gaap Interest Paid
InterestPaid
7855000
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-722000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5177000
CY2015Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
30000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1993000
CY2015Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3607000
CY2015Q1 us-gaap Interest Expense
InterestExpense
4171000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47011000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
117087000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
213000
CY2015Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8444000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2973000
CY2015Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-3750000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
587000
CY2015Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1685000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1811000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
53158000
CY2015Q1 us-gaap Costs And Expenses
CostsAndExpenses
65758000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10303000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2241000
CY2015Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
73434000
CY2015Q1 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5215000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5177000
CY2015Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
10279000
CY2015Q1 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
96740000
CY2015Q1 nktr Royalty Agreement Contingent Payment Description
RoyaltyAgreementContingentPaymentDescription
As a result of worldwide net sales of MIRCERAfor the 12 month periods ended December 31, 2013 and 2012 not reaching certain minimum thresholds.
CY2015Q1 nktr Product Sales And Royalties
ProductSalesAndRoyalties
8099000
CY2015Q1 nktr Estimated Annual Interest Rate On Royalty Liability
EstimatedAnnualInterestRateOnRoyaltyLiability
0.17 pure
CY2015Q1 nktr Potential Development Milestones
PotentialDevelopmentMilestones
128300000
CY2015Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
3962000
CY2015Q1 nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
1039000
CY2015Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
5050000
CY2015Q1 nktr Debt Investment Maximum Maturity Period
DebtInvestmentMaximumMaturityPeriod
Two years or less
CY2015Q1 nktr Debt Investment Maturity Date Description
DebtInvestmentMaturityDateDescription
One year or less

Files In Submission

Name View Source Status
0001193125-15-163717-index-headers.html Edgar Link pending
0001193125-15-163717-index.html Edgar Link pending
0001193125-15-163717.txt Edgar Link pending
0001193125-15-163717-xbrl.zip Edgar Link pending
d901563d10q.htm Edgar Link pending
d901563dex311.htm Edgar Link pending
d901563dex312.htm Edgar Link pending
d901563dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
nktr-20150331.xml Edgar Link completed
nktr-20150331.xsd Edgar Link pending
nktr-20150331_cal.xml Edgar Link unprocessable
nktr-20150331_def.xml Edgar Link unprocessable
nktr-20150331_lab.xml Edgar Link unprocessable
nktr-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending